Tvaster Genkalp Secures $1.25 Mn to Expand Liquid Biopsy Cancer Diagnostics

Tvaster Genkalp Secures $1.25 Mn to Expand Liquid Biopsy Cancer Diagnostics

The investment aims to accelerate the expansion and commercialization of Episcreen Liver, a methylation-based liquid biopsy test designed for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Tvaster Genkalp, a Chennai-based molecular diagnostics startup, has raised $1.25 million in a Pre-Series A funding round led by Ideaspring Capital.

Existing investors include Invigo Softwares and liver transplant specialist Prof. Mohamed Rela.

The investment aims to accelerate the expansion and commercialization of Episcreen Liver, a methylation-based liquid biopsy test designed for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer.

“The funding will accelerate nationwide deployment of Episcreen Liver, offering a non-invasive, highly accurate diagnostic alternative for hepatocellular carcinoma,” said Dr. Srikar Raman, Co-founder of Tvaster Genkalp.

According to Dr Raman, while the current standard screening method, Alpha-Fetoprotein (AFP), has a sensitivity of 50%, Episcreen Liver achieves 90% sensitivity, significantly improving early detection and increasing survival chances by over 70%.

New Diagnostics Pipeline for Oncology

Tvaster is also developing additional oncology diagnostic solutions. The company is advancing its pipeline with Episcreen Bile, a test for cholangiocarcinoma, an aggressive bile duct cancer with limited early detection options.

Additionally, Tvaster has introduced Episcreen HBResist, the first chemotherapy resistance test for pediatric hepatoblastoma, addressing a critical gap in childhood cancer treatment.

To expand accessibility, the company is establishing partnerships with leading diagnostic companies.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Sign In / Sign up